Singapore-based healthtech startup, Neuroglee Therapeutics has secured $2.3m in pre-seed funding. Eisai Co. Ltd, a global pharmaceutical company headquartered in Tokyo, Japan participated in the round along with Kuldeep Singh Rajput, Founder & CEO of Biofourmis. The health-tech startup seeks to use the funding to advance the product pipeline for NG-001, their product which is…